Search results for "CA1"

showing 10 items of 153 documents

Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics

2021

Graphical abstract

ATP Adenosine-triphosphateNBD nucleotide binding domainGSH reduced glutathionePolypharmacologyAlzheimer’s disease (AD)ATP-binding cassette transporterHTS high-throughput screeningBiochemistryABCA7Structural BiologyPLIF protein ligand interactionMSD membrane spanning domainPDB protein data bankTM transmembrane helixABC ATP-binding cassetteMultitarget modulation (PANABC)RMSD root mean square distanceABC transporter (ABCA1 ABCA4 ABCA7)Computer Science ApplicationsMOE Molecular Operating EnvironmentPharmacophoreSNP single-nucleotide polymorphismBiotechnologyResearch ArticleBBB blood-brain barrierBiophysicsDrug designComputational biologyBiologyAD Alzheimer’s diseasePET positron emission tomographyIC intracellular helixAPP amyloid precursor proteincryo-EM cryogenic-electron microscopyGeneticsHomology modelingBinding siteRational drug design and developmentComputingMethodologies_COMPUTERGRAPHICSNBD-cholesterol 7-nitro-2-13-benzoxadiazol-4-yl-cholesterolTransporterPSO particle swarm optimizationPET tracer (PETABC)ECD extracellular domainR-domain/region regulatory domain/regionABCA1biology.proteinEH extracellular helixTP248.13-248.65BODIPY-cholesterol 44-difluoro-4-bora-3a4a-diaza-s-indacene-cholesterolComputational and Structural Biotechnology Journal
researchProduct

CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in he…

2016

Constitutive epimutations of tumor suppressor genes are increasingly considered as cancer predisposing factors equally to sequence mutations. In light of the emerging role of the microenvironment for cancer predisposition, initiation, and progression, we aimed to characterize the consequences of a BRCA1 epimutation in cells of mesenchymal origin. We performed a comprehensive molecular and cellular comparison of primary dermal fibroblasts taken from a monozygous twin pair discordant for recurrent cancers and BRCA1 epimutation, whose exceptional clinical case we previously reported in this journal. Comparative transcriptome analysis identified differential expression of extracellular matrix-r…

Adult0301 basic medicineCancer ResearchTwinsHaploinsufficiencyKetone BodiesExtracellular matrixTranscriptome03 medical and health sciencesCell Line TumormedicineHumansGenes Tumor SuppressorMolecular BiologyPDPNCells CulturedOligonucleotide Array Sequence AnalysisSkinExtracellular Matrix ProteinsbiologyBRCA1 ProteinCell growthGenes HomeoboxCancerDNA MethylationFibroblastsmedicine.diseaseGene Expression Regulation Neoplastic030104 developmental biologyCulture Media ConditionedMutationDNA methylationImmunologyCancer researchbiology.proteinCytokinesCancer-Associated FibroblastsFemaleNeoplasm Recurrence LocalACTA2TranscriptomeResearch PaperEpigenetics
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Biological parameters in breast cancer.

1996

AdultAged 80 and overCA15-3Oncologymedicine.medical_specialtyPloidiesbusiness.industryGeneral NeuroscienceBreast NeoplasmsDNA NeoplasmMiddle AgedPrognosismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyS PhaseBreast cancerHistory and Philosophy of ScienceEvaluation Studies as TopicInternal medicinemedicineHumansFemalebusinessAged
researchProduct

Association of genetic variants with pancreatic cancer

2007

AdultGeneticsCancer ResearchADP-Ribosylation FactorsGenes p16Association (object-oriented programming)Genes BRCA1Genetic variantsAdenocarcinomaMiddle AgedProtein Serine-Threonine KinasesBiologymedicine.diseasePancreatic NeoplasmsAMP-Activated Protein Kinase KinasesRisk FactorsPancreatic cancerMutationGeneticsmedicineHumansFemaleGenetic Predisposition to DiseaseMolecular BiologyCancer Genetics and Cytogenetics
researchProduct

CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-ho…

2001

Summary Background There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic colorectal cancer using palliative chemotherapy. The object of this study was to examine the diagnostic accuracy of monitoring of palliative chemotherapy by means of CEA and CA19-9. Patients and methods The tumour markers CEA and CA 19-9 were subjected to serial measurement in patients with metastatic colorectal cancer (n = 90) using palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-FU with FA and were compared with objective response according to WHO criteria. 85 patients could be evaluated. 43 patients (51%) initially had elevated…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPalliative careCA-19-9 AntigenColorectal cancerLeucovorinSensitivity and SpecificityGastroenterologyDrug Administration ScheduleFolinic acidCarcinoembryonic antigenRecurrenceInternal medicinemedicineHumansInfusions IntravenousAgedTumor markerbiologybusiness.industryPalliative CareHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCarcinoembryonic AntigenSurgeryOncologyFluorouracilbiology.proteinFemaleCA19-9FluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Learning by heart : cardiac cycle reveals an effective time window for learning

2018

Cardiac cycle phase is known to modulate processing of simple sensory information. This effect of the heartbeat on brain function is likely exerted via baroreceptors, the neurons sensitive for changes in blood pressure. From baroreceptors, the signal is conveyed all the way to the forebrain and the medial prefrontal cortex. In the two experiments reported, we examined whether learning, as a more complex form of cognition, can be modulated by the cardiac cycle phase. Human participants ( experiment 1) and rabbits ( experiment 2) were trained in trace eyeblink conditioning while neural activity was recorded. The conditioned stimulus was presented contingently with either the systolic or dias…

AdultMaleBaroreceptorAdolescentPhysiologyComputer sciencehippocampusclassical conditioningtheta oscillationEffective timeStimulus (physiology)verenkiertota3112050105 experimental psychology03 medical and health sciencesYoung Adult0302 clinical medicineHeart RateAnimalsHumans0501 psychology and cognitive scienceshippokampusCA1 Region Hippocampalta515Cardiac cycleGeneral Neuroscience05 social sciencesClassical conditioningAssociation LearningBrainElectroencephalographybaroreceptorMyocardial ContractionConditioning EyelidehdollistuminenAcoustic StimulationNeural processingEvoked Potentials AuditoryFemaleRabbitsNeuroscience030217 neurology & neurosurgeryJournal of Neurophysiology
researchProduct

BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.

2007

PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and familial Breast Cancer (BC) and/or Ovarian Cancer (OC) in patients from Southern Italy (in the region of Sicily) and to identify a possible association between the higher frequency of BRCA1 mutations and a specific familial profile. EXPERIMENTAL DESIGN: A consecutive series of 650 patients with BC and/or OC diagnosed between 1999 and 2005 were recruited from the Southern Italian region of Sicily, after interview at the "Regional Reference Centre for the Characterization and Genetic Screening of Hereditary Tumors" at the University of Palermo. Genetic counselling allowed us to recruit a total…

AdultMaleCancer ResearchGenetic counselingDNA Mutational AnalysisBreast NeoplasmsBiologymedicine.disease_causeGermlineBreast cancermedicineHumansGenetic Predisposition to DiseaseGenetic TestingGenetic testingAgedGeneticsOvarian NeoplasmsMutationPolymorphism Geneticmedicine.diagnostic_testBase SequenceBRCA1 ProteinBRCA1 Genetic testing Breast cancer Ovarian canceCancerMiddle Agedmedicine.diseasePedigreeOncologyItalyMutationFemaleAge of onsetFounder effectBreast cancer research and treatment
researchProduct

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

2008

Male breast cancer (MBC) is a rare and poorly known disease. Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC. Interestingly, BRCA2 germ-line rearrangements have been described in high-risk breast/ovarian cancer families which included at least one MBC case. Germ-line mutations of CHEK2 gene have been also implicated in inherited MBC predisposition. The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations. Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate c…

AdultMaleCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1male breast cancerProtein Serine-Threonine KinasesBiologychek2medicine.disease_causeBreast Neoplasms Malebrca1Breast cancerbrca2medicineHumansBRCA1/BRCA2germ-line mutationsMultiplex ligation-dependent probe amplificationmlpaskin and connective tissue diseasesneoplasmsCHEK2Germ-Line MutationGene RearrangementMutationCancerGene rearrangementmedicine.diseaseCheckpoint Kinase 2Oncologylarge genomic rearrangementsMale breast cancerCancer researchbrca1; brca2; chek2; germ-line mutations; large genomic rearrangements; male breast cancer; mlpaBreast diseaseBreast Cancer Research and Treatment
researchProduct

Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter stud…

2012

Recently, the number of studies on male breast cancer (MBC) has been increasing. However, as MBC is a rare disease there are difficulties to undertake studies to identify specific MBC subgroups. At present, it is still largely unknown whether BRCA-related breast cancer (BC) in men may display specific characteristics as it is for BRCA-related BC in women. To investigate the clinical–pathologic features of MBC in association with BRCA mutations we established a collaborative Italian Multicenter Study on MBC with the aim to recruit a large series of MBCs. A total of 382 MBCs, including 50 BRCA carriers, were collected from ten Italian Investigation Centres covering the whole country. In MBC p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMolecular subtypesSettore MED/06 - Oncologia MedicaDNA Mutational AnalysisGenes BRCA2Genes BRCA1Breast Neoplasms MaleYoung Adultclinical-pathologic features; brca2; brca1; male breast cancer; molecular subtypesBreast cancerInternal medicinemedicineCarcinomaHumansYoung adultFamily historyskin and connective tissue diseasesBRCA1; BRCA2; Clinical-pathologic features; Male breast cancer; Molecular subtypesAgedAged 80 and overGynecologybusiness.industryCarcinoma Ductal BreastMiddle Agedmedicine.diseaseBRCA1BRCA2Male breast cancerItalyOncologyMale breast cancerImmunohistochemistryOvarian cancerbusinessClinical-pathologic featureRare disease
researchProduct